• 1
    A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [see Comments]. N Engl J Med. 1993; 329: 987994.
  • 2
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235242.
  • 3
    Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003; 101: 42794284.
  • 4
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333: 15401545.
  • 5
    Milpied JN, Deconinck E, Colombat P, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004; 350: 12871295.
  • 6
    Mounier N, Gisselbrecht C, Briere J, et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2004; 22: 28262834.
  • 7
    Haddy TB, Adde MA, McCalla J, et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol. 1998; 16: 20702079.
  • 8
    Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994; 12: 25272534.
  • 9
    Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994; 12: 25352542.
  • 10
    Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood. 1994; 84: 957963.
  • 11
    Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol. 1999; 106: 10201026.
  • 12
    Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 31283135.
  • 13
    Micallef IN, Lillington DM, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol. 2000; 18: 947955.
  • 14
    Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000; 95: 15881593.
  • 15
    Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996; 87: 36333639.
  • 16
    Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003; 21: 897906.
  • 17
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244.
  • 18
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999; 17: 38353849.
  • 19
    World Health Organization. Manual of the international statistical classification of disease, injuries and causes of death: based on the recommendations of the Ninth Revision Conference, 1975, and adopted by the Twenty-ninth World Health Assembly, vol. I. Geneva: World Health Organization, 1977.
  • 20
    Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer, 2000.
  • 21
    Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999; 18: 695706.
  • 22
    Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant. 1990; 5: 173177.
  • 23
    Brockstein BE, Smiley C, Al-Sadir J, Williams SF. Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors. Bone Marrow Transplant. 2000; 25: 885894.
  • 24
    van Besien K, Tabocoff J, Rodriguez M, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant. 1995; 15: 549555.
  • 25
    Epelbaum R. Non-Hodgkin's lymphoma: long-term survivors and adverse effects. Ann Oncol. 2000; 11( Suppl 3): 123128.
  • 26
    Pavlovsky S, Juni M, Milone G, Martinez-Rolon J, Fernandez I, Corrado C. Ten years of autologous peripheral stem cell transplantation with the same conditioning regimen (CBV) in 279 consecutive lymphoma patients done in a single center. Evaluation of prognostic factors affecting outcome. Proc Am Soc Clin Oncol. 2003; 22: 607 (Abstract 2441).
  • 27
    Buadi FK, Micallef IN, Ansell SM, Porrata LF, Inwards DJ. High dose therapy with autologous stem cell transplantation (ASCT) for non-Hodgkin's lymphoma (NHL) in elderly patients. A single institution retrospective study. Blood. 2003; 102 (Abstr 2719).
  • 28
    Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 22082214.
  • 29
    Andre M, Mounier N, Leleu X, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004; 103: 12221228.
  • 30
    Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003; 101: 20152023.
  • 31
    Park S, Brice P, Noguerra ME, et al. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 2000; 26: 321326.